VACCINES (US industry forecasts for 2014 & 2019) published by The Freedonia Group in August, 2010. This report consists of 239 PAGES and the price starts from US $ 4700.
Abstract
US demand to grow 5.5% annually through 2014
Demand for vaccines is forecast to increase 5.5 percent annually to more than
$14 billion in 2014. The market has experienced dramatic growth due to
increasing routine seasonal influenza immunization and the rising number of
preventive and booster vaccines available for adults and adolescents. This
growth will be compounded as several new therapeutic vaccines for cancer reach
the market, followed in the coming years by biological treatments for
Respiratory Syncytial Virus (RSV) and Alzheimer' s Disease, and a variety of
new vaccines for travel and biodefense.
New routine vaccines to boost adult, adolescent segment
Pediatric vaccines have been the mainstay of the vaccine market for many
years, growing steadily as new products emerged and as a greater number of
routine vaccinations were encouraged. Now, a substantial number of primary
vaccines and boosters are being recommended for adolescents and older adults,
and the market for vaccines has expanded dramatically with the addition of
these populations to the target markets for vaccine producers.
Significant growth in the market has been fueled by the introduction of a
vaccine for Human Papillomavirus (HPV), recommended for girls and young women
and now being considered for males and wider age range. Seasonal influenza
vaccination is also gaining ground and represents a substantial portion of
growth in adult vaccines, as new preventive treatments against zoster and
meningococcal disease. Also a factor in adult vaccines is the growing use of
boosters against tetanus, diphtheria, pertussis and other diseases.
Combination vaccines to pace pediatric products
Among vaccines for children, sales will be affected by the expiration of
patent protection for many of the most widely used vaccines. This has
encouraged producers to develop several new combination vaccines, which will
serve to maintain the value of products while decreasing the burden of
multiple individual injections. Traditional DTaP (diphtheria, tetanus,
pertussis) vaccines are being supplemented by products for Hepatitis B and
polio or Haemophilus b. Also being developed are vaccines to address a wider
range of bacterial serotypes, as with Wyeth' s blockbuster PREVNAR7, which has
been expanded to address 13 serotypes and which is recommended as a supplement
for children who already received the earlier vaccine. Relatively new
vaccines, such as that for Rotavirus, continue to mature and to reach greater
immunization coverage.
Many new therapeutic vaccines showing promise
Vaccine demand will be spurred considerably by a number of therapeutic
vaccines for cancer that are nearing completion of clinical trials and are
poised for FDA approval. There are currently 50 cancer vaccines in phase III
or later trials, and the activity surrounding cancer vaccine development is
expected to continue at a high pace. Also showing promise are vaccines being
developed for RSV, HIV and Alzheimer' s Disease. Similarly, a range of vaccines
for travel, developing countries and biodefense are in the pipeline, including
prophylactics for malaria, hemorrhagic fevers, West Nile virus and plague.
Study coverage
This new Freedonia industry study, Vaccines, presents historical demand data
(1999, 2004 and 2009) plus forecasts for 2014 and 2019 by major and minor
product group. The study also considers market environment factors, details
industry structure, evaluates company market share and profiles 17 industry
participants.
Table of Contents
INTRODUCTION
I. EXECUTIVE SUMMARY
II. MARKET ENVIRONMENT
- General
- Macroeconomic Outlook
- Demographic Patterns
- Health Care Trends
- Health Insurance & Reimbursement
- Medical Conditions
- Chronic Conditions
- Acute Conditions
- Reportable Diseases
- National Health Expenditures
- Medical Facilities & Professionals
- Patient Activity
- Animal Health Care
- Animal Demographic Trends
- Veterinarians & Other Veterinary Workers
- Animal Health Expenditures
- Regulatory Considerations
- Human Vaccines Regulation
- Animal Vaccines Regulation
III. VACCINE TECHNOLOGIES
- General
- Technologies Used in Currently Licensed Products
- Technologies Under Development
- Delivery
- Valence & Combined Vaccines
- Efficacy
IV. PRODUCT OVERVIEW
- General
- Major Product Groups
- Human Vaccines
- Recommended Childhood Immunizations
- Recommended Adult & Adolescent Immunizations
- Animal Vaccines
- Historical Market Trends
- International Activity & Foreign Trade
- Human Vaccines Trade
- Animal Vaccines Trade
V. HUMAN VACCINES
- General
- Pediatric Vaccines
- Combination Vaccines
- Diphtheria-Tetanus-Pertussis (DTaP)
- Measles-Mumps-Rubella (MMR)
- Other Combination Vaccines
- Pneumococcal (PCV)
- Varicella
- Rotavirus
- Hepatitis
- Haemophilus b (Hib)
- Pediatric Seasonal Influenza
- Polio
- Adult & Adolescent Vaccines
- Seasonal Influenza Vaccines
- Human Papillomavirus
- Tetanus-Diphtheria-Pertussis (Tdap)
- Meningococcus
- Pneumococcus
- Hepatitis
- Herpes Zoster
- Other Adult & Adolescent Vaccines
- Varicella
- Tuberculosis
- Lyme Disease
- Pandemic Influenza Vaccines
- Biodefense
- Travel Vaccines
- Developmental Vaccines
- Cancer
- Prostate Cancer
- Lung Cancer
- Other Cancers
- Other Developmental Vaccines
- HIV/AIDS
- Respiratory Syncytial Virus (RSV)
- Alzheimer' s Disease
- All Other Developmental Vaccines
VI. ANIMAL VACCINES
- General
- Livestock Vaccines
- Bovine Vaccines
- Porcine Vaccines
- Ovine Vaccines
- Companion Animal Vaccines
- Canine Vaccines
- Feline Vaccines
- Equine Vaccines
- Other Companion Animal Vaccines
- Poultry Vaccines
- Other Animal Vaccines
VII. INDUSTRY STRUCTURE
- General
- Market Share
- Competitive Strategies
- Mergers & Acquisitions
- Licensing & Related Agreements
- Research & Development
- Manufacturing
- Marketing & Distribution
COMPANY PROFILES
- AstraZeneca plc
- Baxter International Incorporated
- Biogen Idec Incorporated
- Boehringer Ingelheim GmbH
- Crucell NV
- Dow Chemical Company
- DynPort Vaccine Company LLC
- Emergent BioSolutions Incorporated
- GenVec Incorporated
- GlaxoSmithKline plc
- Heska Corporation
- Intervet/Schering-Plough Animal Health, see Merck
- MedImmune LLC, see AstraZeneca
- Merck & Company Incorporated
- Merial Limited, see Sanofi-Aventis
- Novartis AG
- Pfizer Incorporated
- PharmAthene Incorporated
- Sanofi-Aventis
- VaxGen Incorporated
- VaxInnate Corporation
- Wyeth, see Pfizer
- Additional Companies Mentioned in the Study
LIST OF TABLES
SECTION I -- EXECUTIVE SUMMARY
SECTION II -- MARKET ENVIRONMENT
- 1 Macroeconomic Indicators
- 2 Population & Households
- 3 Health Insurance Coverage of the US Population
- 4 Chronic Conditions by Type
- 5 Acute Conditions by Type
- 6 Specified Reportable Diseases
- 7 National Health Expenditures
- 8 Selected Medical Facilities & Professionals
- 9 Patient Activity
- 10 Animal Population
- 11 Animal Health Employment
- 12 Animal Health Expenditures
SECTION III -- VACCINE TECHNOLOGIES
- 1 US Licensed Vaccines by Production Technology
SECTION IV -- PRODUCT OVERVIEW
- 1 Vaccines Demand by Major Product Group
- 2 Human Vaccines Licensed for US Sale
- 3 2010 CDC-Recommended Childhood Immunizations
- 4 2010 CDC-Recommended Adolescent Immunizations
- 5 2010 CDC-Recommended Adult Immunizations
- 6 Vaccines Market, 1999-2009
- 7 US Trade in Vaccines
- 8 US Trade in Human Vaccines
- 9 US Trade in Animal Vaccines
SECTION V -- HUMAN VACCINES
- 1 Human Vaccines Demand
- 2 Pediatric Vaccines Demand by Type
- 3 Pediatric Combination Vaccines Demand
- 4 Diphtheria, Tetanus & Pertussis (DTaP) Combination Vaccines Demand
- 5 Measles, Mumps & Rubella (MMR) Combination Vaccines Demand
- 6 Other Combination Vaccines Demand
- 7 Pediatric Pneumococcal Vaccines Demand
- 8 Varicella Vaccines Demand
- 9 Rotavirus Vaccines Demand
- 10 Pediatric Hepatitis A & B Vaccines Demand
- 11 Haemophilus b (Hib) Vaccines Demand
- 12 Pediatric Seasonal Influenza Vaccines Demand
- 13 Polio Vaccines Demand
- 14 Adult & Adolescent Vaccines Demand by Group & Condition
- 15 Adult & Adolescent Seasonal Influenza Vaccines Demand
- 16 Human Papillomavirus (HPV) Vaccines Demand
- 17 Tetanus-Diphtheria-Pertussis (Tdap) Vaccines Demand
- 18 Meningococcal Vaccines Demand
- 19 Adult & Adolescent Pneumococcal Vaccines Demand
- 20 Adult & Adolescent Hepatitis A & B Vaccines Demand
- 21 Herpes Zoster Vaccines Demand
- 22 Other Adult & Adolescent Vaccines Demand
- 23 Pandemic Influenza Vaccines Demand
- 24 Biodefense Vaccines Demand
- 25 Travel Vaccines Demand
- 26 Developmental Vaccines Demand
- 27 Cancer Vaccines Demand
- 28 Other Developmental Vaccines Demand
SECTION VI -- ANIMAL VACCINES
- 1 Animal Vaccines Demand
- 2 Livestock Vaccines
- 3 Companion Animal Vaccines Demand
- 4 Poultry Vaccines Demand
- 5 Other Animal Vaccines Demand
SECTION VII -- INDUSTRY STRUCTURE
- 1 US Vaccines Revenues by Company, 2009
- 2 Selected Acquisitions & Divestitures
- 3 Selected Cooperative Agreements
LIST OF CHARTS
SECTION VII -- INDUSTRY STRUCTURE
- 1 US Human Vaccines Market Share by Company, 2009
- 2 US Animal Vaccines Market Share by Company, 2009
